🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“The life expectancy of patients with cancer-associated thrombosis is improving. The risk of recurrent VTE declines over time, whereas the risk of bleeding remains substantial,” Mahé Isabelle discussed the results of the API-CAT trial at #ACC25. bit.ly/4ciFK6I #cvVTE

Interesting comments from Geoff Barnes about the #APICAT study #VTE #cancer @ACC25 Assistance Publique – Hôpitaux de Paris (AP-HP) INNOVTE

Study API-CAT: Low-dose apixaban proved noninferior to full-dose for extended #VTE prevention in active cancer—with significantly less bleeding. Practice-changing. bit.ly/3E4UxFk #ACC25 #Oncology Mahé Isabelle Diego Sadler MD FACC Simon Noble NEJM

#API-CAT study. -Full text nejm.org/doi/full/10.10… -See comments below #cancer #thrombosis NEJM Assistance Publique – Hôpitaux de Paris (AP-HP) INNOVTE ISTH

New Paper Alert: Reduced-Dose Apixaban Found Effective for Extended Treatment of Cancer-Associated VTE Mahé Isabelle Marc Carrier Mayeur Didier Juan José López Núñez Robert-Ebadi Helia oncodaily.com/oncolibrary/re… #AnticoagulantTherapy #Apixaban #CancerCare #MedX #MedEd #OncoDaily #Oncology

📽️ Isabelle Mahé shares her insights API-CAT trial were presented at #ACC25. -> medicaldigest.org/scientific-con… Mahé Isabelle ACC Media Center American College of Cardiology #CardioTwitter

#API-CAT trial #cancer#anticoagulant #ACC25

In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary:

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism Extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for the prevention of recurrent venous thromboembolism in patients with active cancer nejm.org/doi/full/10.10…

#API-CAT Study study just published in NEJM

NEJM | API-CAT 💊💊 Apixaban 2,5 mg x2/j ≈ 5 mg x2/j après 6 mois chez patients #cancer & #MTEV 🟰Incidence récidive : 2,1% vs 2,6% N. 🩸Moins de saignement: 12,1 vs 15,6 S ➡️ Non infériorité + meilleur profil de tolérance nejm.org/doi/full/10.10… Mahé Isabelle OncoAlert

#API-CAT Study study just published in NEJM

Original Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT) nej.md/41YkRZK Editorial: Cancer-Associated Venous Thromboembolism — Beyond 6 Months nej.md/4iB6wcA #Cardiology

Study API-CAT: Extended low-dose #Apixaban (2.5 mg BID) is noninferior to full-dose for #VTE prevention in cancer—with less bleeding. A potential practice-changer. bit.ly/4jjl4h5 Mahé Isabelle #ACC25 #VTE #Oncology

💊 Discontinuation of #VKA in patients with life-limiting disease ⬇️ 📌 Among 18,000+ 🇳🇱 VKA users, >80% continued anticoagulant until 1 month before death 📌 Similar rates of bleeding and thromboembolism during and after VKA discontinuation 🆓👉 thieme-connect.de/products/ejour…

Study API-CAT: Low-dose apixaban proved noninferior to full-dose for extended #VTE prevention in active cancer—with significantly less bleeding. Practice-changing. bit.ly/3E4UxFk #ACC25 #Oncology Mahé Isabelle Diego Sadler MD FACC Simon Noble NEJM

Best. Present. Ever.

How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! RPTH doi.org/10.1016/j.rpth…

How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! RPTH ISTH European Society of Cardiology Journals doi.org/10.1016/j.rpth…